Shionogi completes $2.5B acquisition of RADICAVA (edaravone) from Tanabe Pharma, securing global ALS rights as Tanabe refocuses on pipeline investment.
Written By: Anand Sathappan BPharm
Reviewed By: Pharmacally Editorial Team
Shionogi & Co., Ltd. has completed the acquisition of full global rights to RADICAVA (edaravone) from Tanabe Pharma Corporation, with the transfer formally effective April 1, 2026. The deal covers intellectual property and commercial rights across major markets, including Japan, the United States, and Canada, with additional regional transfers to follow pending local procedures.
RADICAVA is approved by the U.S. Food and Drug Administration and other global regulators for the treatment of Amyotrophic Lateral Sclerosis, a progressive condition with limited treatment options and no cure. The therapy is available in both intravenous and oral suspension formulations and has been used to treat more than 22,000 patients in the United States.
Strategic Realignment for Both Companies
For Shionogi, the acquisition strengthens its rare disease portfolio and commercial infrastructure. CEO Isao Teshirogi stated that the deal supports the company’s long-term vision while also transferring responsibility for continued care and innovation in ALS.
From Tanabe Pharma’s perspective, the divestment marks a strategic shift toward reinforcing its financial base and advancing its clinical pipeline. CEO Akihisa Harada indicated that proceeds from the transaction will support future investments, including research and development and partnership-driven pipeline expansion, particularly in Japan. The company emphasized its continued focus on addressing unmet medical needs, including rare diseases, through both internal innovation and external collaborations.
Financial Terms and Commercial Impact
Under the agreement announced in December 2025, Shionogi paid $2.5 billion upfront through its U.S. subsidiary and may make additional royalty payments tied to future sales. The transaction is expected to be immediately accretive in fiscal year 2026, contributing approximately $700 million in annual global revenue.
Product Profile and Clinical Use
RADICAVA ORS (edaravone), approved by the FDA in May 2022, provides an oral alternative to intravenous administration, reducing treatment burden. In 2024, the therapy received orphan drug exclusivity in the U.S. based on its contribution to patient care.
The treatment is administered in cycles, beginning with a 14-day dosing period followed by a drug-free interval, with adjusted schedules in subsequent cycles. Common adverse events include contusion, gait disturbance, and headache, while hypersensitivity and sulfite-related allergic reactions remain key safety considerations.
Disease Background
ALS is a rare, progressive neurodegenerative disorder characterized by motor neuron loss, leading to muscle weakness, respiratory decline, and reduced survival. Global incidence is estimated at 1–2 cases per 100,000 population annually, and treatment options remain limited.
With the transaction complete, Shionogi assumes full global control of RADICAVA, while Tanabe Pharma redirects resources toward pipeline innovation and long-term growth initiatives.
Reference
Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone), 01 April 2026, Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone) | Shionogi Inc.
Notice Regarding Completion of Business Transfer of Edaravone, 02 April 2026, April 2, 2026 Notice Regarding Completion of Business Transfer of Edaravone